Does a 16-week fenofibrate treatment increase LDL particle size in type IIA dyslipidemic patients?
As pravastatin treatment had no effect on LDL size, it is suggested that the additional effect of fenofibrate therapy on LDL size may contribute to reduce the risk of coronary heart disease (CHD) beyond what can be expected from the reduction in LDL cholesterol concentration in type IIa dyslipidemic patients.
This case report identified a musician with CUWP and HMS. Joint hypermobility syndrome does not merely involve joint laxity, but involves connective tissue impairment throughout the body as well as perhaps involving the body's neurological system. Joint hypermobility is common in musicians.